Exagen Inc. (XGN) stock

XGNNasdaqServices-Medical LaboratoriesFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/3015% above fair value

$4.13−0.28 (-6.35%)

Close on Nov 13, 2026Market cap $100.05MP/E –Yield –

Exagen EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Exagen has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is XGN.

Revenue growth13.7% · median 17.2%

Gross margin58.7% · median 46.9%

Operating margin-20.1% · median -87.7%

Net margin-25.1% · median -86.7%

Advertisement
300 × 250

See a number that looks wrong?